Relation of Ventricular Tachycardia/Fibrillation to Beta-Blocker Dose Maximization Guided by Pacing Mode Analysis in. Nonpacemaker-Dependent Patients With Implantable Cardioverter-Defibrillator

被引:5
|
作者
Deftereos, Spyridon [1 ]
Giannopoulos, Georgios [1 ]
Kossyvakis, Charalampos [1 ]
Kaoukis, Andreas [1 ]
Raisakis, Konstantinos [1 ]
Panagopoulou, Vasiliki [1 ]
Ntzouvara, Olga [1 ]
Perpinia, Anastasia [1 ]
Rentoukas, Ilias [1 ]
Pyrgakis, Vlasios [1 ]
Manolis, Antonios S. [2 ]
Stefanadis, Christodoulos [3 ]
机构
[1] Athens Gen Hosp G Gennimatas, Dept Cardiol, Athens, Greece
[2] Evaggelismos Hosp, Cardiol Dept 1, Athens, Greece
[3] Univ Athens, Sch Med, Cardiol Dept 1, Hippokrate Hosp, GR-11527 Athens, Greece
关键词
HEART; SURVIVAL; CARDIOMYOPATHY; PREVENTION; AMIODARONE;
D O I
10.1016/j.amjcard.2011.02.321
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We hypothesized that uptitration of beta blockade and adjustment of pacing parameters to achieve a prevalence of single chamber atrial inhibited rate-responsive (AAIR) pacing in patients with dual-chamber implantable cardioverter-defibrillators (ICDs) would result in maximization of beta-blocker dosage and thus decrease appropriate ICD therapies. We included patients with ischemic or dilated cardiomyopathy and implanted ICDs without contraindications to beta blockers and atrioventricular conduction disturbances. Two 6-month periods were compared: clinically guided phase (pacing function set at back-up dual-chamber rate-responsive pacing mode at a lower rate of about 40 beats/min) and pacing-guided phase, during which beta-blocker dosage was titrated with a target of achieving >90% AAIR pacing (lower rate 60 beats/min). Sixty-one patients (64.2 +/- 8.3 years old) were included. During the pacing-guided phase the target of >= 90% AAIR pacing was achieved in 80.3% of patients. Mean metoprolol dose during the clinically guided phase was 96.7 +/- 29.4 versus 127.0 +/- 39.6 mg/day in the pacing-guided phase (p <0.001). Appropriate ICD therapies were recorded in 35 patients (57.4%) during the clinically guided phase versus 20 (32.8%) during the pacing-guided phase (p <0.001; 1.15 and 0.48 appropriate ICD therapies per patient, respectively, p <0.001). In multivariate analysis, AAIR pacing and beta-blocker dose were inversely related to appropriate ICD therapies. In conclusion, a pacing-guided approach for maximizing beta-blocker doses guided by maximizing AAIR pacing in patients with ICDs may be beneficial compared to the conventional strategy. This pacing-guided approach led to higher daily beta-blocker doses, which were correlated to fewer appropriate ICD therapies. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011; 107:1812-1817)
引用
收藏
页码:1812 / 1817
页数:6
相关论文
共 5 条
  • [1] Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect
    Jimenez-Candil, Javier
    Hernandez, Jesus
    Martin, Ana
    Ruiz-Olgado, Maria
    Herrero, Jesus
    Ledesma, Claudio
    Morinigo, Jose
    Martin-Luengo, Candido
    EUROPACE, 2010, 12 (09): : 1231 - 1238
  • [2] Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverter-defibrillator
    Hoogwegt, Madelein T.
    Kupper, Nina
    Theuns, Dominic A. M. J.
    Jordaens, Luc
    Pedersen, Susanne S.
    EUROPACE, 2012, 14 (01): : 74 - 80
  • [3] Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone
    Schupp, Tobias
    Behnes, Michael
    Kim, Seung-hyun
    Mueller, Julian
    Weidner, Kathrin
    Reiser, Linda
    Huseynov, Aydin
    Bollow, Armin
    Borggrefe, Martin
    Taton, Gabriel
    Reichelt, Thomas
    Ellguth, Dominik
    Engelke, Niko
    Akin, Muharrem
    Meininghaus, Dirk Grosse
    Bertsch, Thomas
    Akin, Ibrahim
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (03) : 493 - 502
  • [4] Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator patients: Insights from the German DEVICE registry
    Wiedmann, Felix
    Ince, Hueseyin
    Stellbrink, Christoph
    Kleemann, Thomas
    Eckardt, Lars
    Brachmann, Johannes
    Gonska, Bernd -Dieter
    Kaeaeb, Stefan
    Perings, Christian A.
    Jung, Werner
    Lugenbiel, Patrick
    Hochadel, Matthias
    Senges, Jochen
    Frey, Norbert
    Schmidt, Constanze
    HEART RHYTHM, 2023, 20 (04) : 501 - 509
  • [5] Non-linear Association Between Body Mass Index and Ventricular Tachycardia/Ventricular Fibrillation in Patients With an Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy Defibrillator: A Multicenter Cohort Study
    Zhou, Bin
    Zhao, Shuang
    Tang, Min
    Chen, Keping
    Hua, Wei
    Su, Yangang
    Yang, Jiefu
    Liang, Zhaoguang
    Xu, Wei
    Zhang, Shu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7